Sandoz launches Xgeva, Prolia biosimilars
Sandoz is introducing Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz, the first and only interchangeable FDA-approved denosumab biosimilars and are approved to treat all indications of Amgen’s Xgeva (denosumab) and Amgen’s Prolia (denosumab).
This launch builds on Sandoz established leadership in biosimilars and oncology dating back to the introduction of the first biosimilar in the United States in 2015.
Wyyost and Jubbonti are key biosimilar value drivers that are integral to the Sandoz growth strategy, representing a significant step forward in advancing the company’s ambition to be the biosimilar leader in the United States, the company said.
Keren Haruvi, president of Sandoz North America, said, “Denosumab is a vital medicine for conditions such as osteoporosis and cancer-related skeletal events. Providing an additional high-quality, cost-effective treatment option helps improve access and affordability for U.S. patients.”
[Read more: AAM report: Generics, biosimilars generate $445B in savings]
Sandoz said Wyost and Jubbonti have the same dosage form, route of administration, dosing regimen and presentation as the respective reference medicines. Wyost and Jubbonti are approved as interchangeable with the reference medicines for all indications. Wyost and Jubbonti will be launching with an established Q code.
Sandoz shared that it is providing comprehensive support resources for patients who are prescribed Wyost and Jubbonti, including reimbursement and financial support.
Claire Gill, CEO of the Bone Health and Osteoporosis Foundation, said, “Bone loss and cancer-related skeletal complications can have a profound impact on patients’ lives, but access to effective treatments has often been impacted by cost. With the introduction of new biosimilar options, patients now have access to more treatments they need and deserve.”
[Read more: Sandoz inks license agreement with Henlius for Yervoy biosimilar]